Suchergebnisse - "Neurath, Markus F"

PubPharm (27)

1

Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease

enthalten in: Journal of Crohn's & colitis | 2023

von Schulze, L. | Becker, E. | Dedden, M. | +18

2

Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing

enthalten in: Clinical and translational medicine | 2023

von Sommer, K. | Heidbreder, K. | Kreiss, L. | +12

3

Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease

enthalten in: Translational research : the journal of laboratory and clinical medicine | 2023

von Schneider, I. | Allner, C. | Mühl, L. | +12

4

Controlling in and out - the future of interfering with immune cell trafficking in inflammatory bowel disease

enthalten in: Expert review of clinical immunology | 2023

von Zundler, S. | Schulze, L. | Neurath, M.

5

The Memory T Cell "Communication Web" in Context with Gastrointestinal Disorders-How Memory T Cells Affect Their Surroundings and How They Are Influenced by It

enthalten in: Cells | 2022

von Knauss, A. | Gabel, M. | Neurath, M. | +1

6

Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab

enthalten in: Gut | 2022

von Becker, E. | Dedden, M. | Gall, C. | +12

CommentIn: Gut. 2022 Aug;71(8):1455-1456. - PMID 34497148

7

Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets

enthalten in: Clinical and translational gastroenterology | 2022

von Becker, E. | Schweda, A. | Ullrich, K. | +6

8

Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis

enthalten in: Therapeutic advances in gastroenterology | 2022

von Besendorf, L. | Müller, T. | Geppert, C. | +7

9

Vedolizumab-associated enthesitis : correlation or causality?

enthalten in: Rheumatology (Oxford, England) | 2021

von Vitali, F. | Simon, D. | Neurath, M. | +2

CommentOn: Rheumatology (Oxford). 2021 Dec 1;60(12):5809-5813. - PMID 33580246

10

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients : a cohort study

enthalten in: BMC gastroenterology | 2021

von Mühl, L. | Becker, E. | Müller, T. | +4